Psomagen Past Earnings Performance

Past criteria checks 0/6

Psomagen's earnings have been declining at an average annual rate of -128342.1%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 14.7% per year.

Key information

-128,342.1%

Earnings growth rate

-128,999.8%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-14.7%
Return on equity-20.7%
Net Margin-18.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In Growth

Aug 28
Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In Growth

A Look At The Fair Value Of Psomagen, Inc. (KOSDAQ:950200)

Jul 05
A Look At The Fair Value Of Psomagen, Inc. (KOSDAQ:950200)

We're Not Very Worried About Psomagen's (KOSDAQ:950200) Cash Burn Rate

Jan 13
We're Not Very Worried About Psomagen's (KOSDAQ:950200) Cash Burn Rate

Revenue & Expenses Breakdown

How Psomagen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A950200 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2434,069-6,15210,5851,353
31 Mar 2433,336-6,0449,9021,353
31 Dec 2332,275-4,2888,5861,353
30 Sep 2335,151-2,3657,9801,943
30 Jun 2339,92158,2071,943
31 Dec 2243,374-1,04810,5531,943

Quality Earnings: A950200 is currently unprofitable.

Growing Profit Margin: A950200 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A950200's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A950200's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A950200 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Return on Equity

High ROE: A950200 has a negative Return on Equity (-20.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies